title: Therapy-related myeloproliferative neoplasm with ETV6-PDGFRB rearrangement following treatment of acute promyelocytic leukemia.
authors.forename: Jean-Valère
authors.initials: JV
authors.lastname: Malfuson
authors.forename: Johanna
authors.initials: J
authors.lastname: Konopacki
authors.forename: Thierry
authors.initials: T
authors.lastname: Fagot
authors.forename: François
authors.initials: F
authors.lastname: Desangles
authors.forename: Dominique
authors.initials: D
authors.lastname: Bories
authors.forename: Bertrand
authors.initials: B
authors.lastname: Souleau
authors.forename: Thierry
authors.initials: T
authors.lastname: de Revel
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D015321:Gene Rearrangement; D006801:Humans; D007621:Karyotyping; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy / Q000235:genetics; D008297:Male; D008875:Middle Aged; D009196:Myeloproliferative Disorders / Q000139:chemically induced* / Q000235:genetics*; D015514:Oncogene Proteins, Fusion / Q000235:genetics*; D014178:Translocation, Genetic; D014212:Tretinoin / Q000009:adverse effects / Q000627:therapeutic use; D020797:Receptor, Platelet-Derived Growth Factor beta; D000097764:ETS Translocation Variant 6 Protein
chemical_list: D000970:Antineoplastic Agents; D015514:Oncogene Proteins, Fusion; D014212:Tretinoin; C464679:ETV6-PDGFRB fusion protein, human; D020797:Receptor, Platelet-Derived Growth Factor beta; D000097764:ETS Translocation Variant 6 Protein